Ironwood Pharmaceuticals A
IRWDAlgoritmens signaler
- ›Starkt 6m-momentum (+153.0%)
- ›Starkt 12m-momentum (+346.7%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (87% årlig)
- ›+697% från 52v-botten
- ›Svagt 3m-momentum (-18.3%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsIronwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
7 h sedanIronwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 MSN
MSN[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
16 h sedan[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing Stock Titan
Stock TitanBank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals - Stock Titan
1 d sedanBank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals Stock Titan
Stock TitanIRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
5 d sedanIRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) ChartMill
ChartMillIRWD Price Today: Ironwood Pharmaceuticals, Inc. - Stock Price, Quote & Chart | MEXC - MEXC Exchange
5 d sedanIRWD Price Today: Ironwood Pharmaceuticals, Inc. - Stock Price, Quote & Chart | MEXC MEXC Exchange
MEXC ExchangeIRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
5 d sedanIRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) ChartMill
ChartMillIronwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance - Quiver Quantitative
2026-01-02Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance Quiver Quantitative
Quiver QuantitativeIronwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
2025-11-10Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today repo
Ironwood Pharmaceuticals ABusinesswireWhy Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
2025-10-14Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term Yahoo Finance
Yahoo FinanceIronwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
2025-08-07Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today repo
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals Reports First Quarter 2025 Results
2025-05-07Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today repo
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2025-04-30Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
2025-04-25Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today anno
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
2025-04-22Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced t
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
2025-04-14Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today anno
Ironwood Pharmaceuticals ABusinesswireIronwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
2025-03-27Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare dise
Ironwood Pharmaceuticals ABusinesswire